Depression risk increases in perimenopause, and depression is cited
1-3 as a primary reason for resuming menopausal hormone therapy (HT). Community-based epidemiologic studies
4-8 have documented a 1.5- to 3-fold greater risk of first onset of depression and recurrent depression in women in perimenopause compared with those who are premenopausal or several years postmenopausal. Observational studies
9-11 have reported the emergence of depressive symptoms after the discontinuation of HT in 5% to 10% of women.